The only earbuds on the market that analyze your hearing profile to generate truly custom sound made just for you

Masimo (NASDAQ: MASI), a global leader in innovative noninvasive monitoring technologies, and Denon, a pioneer in audio technology with over a century of audio expertise, proudly unveil the latest evolution of its acclaimed Denon PerL™ and Denon PerL Pro™ True Wireless earbud lineup with the introduction of White PerL. Denon PerL represents the epitome of personalized audio listening.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240516300869/en/

Denon PerL™ and PerL Pro™ (Photo: Business Wire)

The two Denon PerL models are engineered with Masimo’s proprietary Adaptive Acoustic Technology™ (AAT™) to deliver the only earbud that puts hearing personalization at the forefront of the listening experience. Masimo AAT works by detecting an individual’s inner ear response from carefully curated sound frequencies sent into the ear canal and then creating a custom hearing profile based on each individual’s hearing sensitivities – helping to enhance sound depth, detail, and clarity for a superior listening experience.

Joe Kiani, Founder and CEO of Masimo, stated, “PerL continues to propel us into a new era of personalized listening, and Masimo is proud to lead the charge. With our Adaptive Acoustic Technology integrated into Denon’s PerL earbuds, we’re not just changing the way we listen to music; we’re revolutionizing the future where every individual can enjoy sound tailored precisely to their unique hearing profile, setting a new standard for immersive audio.”

Masimo’s AAT has raised the bar to new heights for personalized audio. By harnessing Masimo’s expertise, Denon PerL goes beyond conventional audio tuning, ensuring that each user’s unique hearing profile is fully understood.

Your Music Tuned Your Way

From person to person, hearing differences impact the listening experience. Denon PerL with Masimo AAT automatically tunes the sound based upon each individual’s inner ear response to enhance sound depth, details, and clarity for a supreme personalized listening experience. The Denon PerL Headphone app for iOS and Android simplifies the creation of your personalized hearing profile through a step-by-step adjustment process. The app also allows you to adjust listening settings and change your bass and treble equalization preferences while still using your optimized hearing profile.

Elevating the Audio Experience with Denon’s Legacy of Excellence

Drawing from over a century of audio mastery, Denon ensures that both PerL models embody the brand’s signature sound superiority. By combining the brand’s renowned signature spacious and vivid sound with Masimo’s cutting-edge technology, Denon PerL offers unmatched depth, detail, and clarity every session.

Unparalleled Versatility and Functionality

In addition to personalized sound, the Denon PerL earbuds boast an array of features designed to adapt to the user’s lifestyle seamlessly. One of the problems with many earbuds is that they easily fall off the ear. This problem has been substantially reduced due to Denon PerL’s unique mechanical design.

Whether immersing oneself in music with active noise cancellation or staying connected to the surroundings with social mode, Denon PerL has features to accommodate a variety of lifestyles. Enjoy advanced functions with Denon PerL Pro such as spatial audio, which creates a more immersive surround sound atmosphere in a compact and comfortable format, and adaptive active noise cancellation that dynamically adjusts to each user’s environment.

Discover the power of truly personalized listening, as Denon redefines the audio experience. The new color of Denon PerL and Denon PerL Pro is now available at www.Denon.com for $199 and $349, respectively.

@Masimo | #Masimo

About Denon

Denon, a leading manufacturer of premium audio equipment, is dedicated to delivering the ultimate listening experience to music lovers worldwide. Since 1910, Denon has been at the forefront of technological advancements in audio engineering, setting the standard for high-quality sound systems that are built to last and cater to the diverse needs of music enthusiasts, from audiophiles to casual listeners. For more information, visit Denon.com.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97® and the Masimo W1® medical watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº®, Masimo W1 Sport, and Masimo Stork™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

  1. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  2. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  3. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  4. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  5. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  6. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  7. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
  8. Estimate: Masimo data on file.
  9. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo AAT™ and its incorporation into the two Denon PerL models. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo's unique technologies, including AAT, as well as the incorporation of such technologies into Denon Perl Models, contribute to better listening experience; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Media Contact: Masimo Matt Whewell 720-838-0691 Matt.whewell@masimo.com

Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Masimo Charts.
Masimo (NASDAQ:MASI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Masimo Charts.